May. 18 at 9:38 PM
$BNTX here are the abstracts they submitted
* “First report of efficacy and safety results from a phase 2 trial evaluating BNT327/PM8002 plus chemotherapy as first-line treatment in unresectable malignant mesothelioma.”
* “DB-1311/BNT324 (a novel B7H3 ADC) in patients with castrate-resistant prostate cancer (CRPC).”
* “First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients with CLDN6-positive advanced solid tumors.”
* “A global Phase 3 double-blind, randomized trial of BNT327/PM8002 plus chemotherapy compared to atezolizumab plus chemo in patients with first-line extensive-stage small cell lung cancer (ES-SCLC).”
